Skip to main content

Table 2 Identification of antibodies to high risk human papilloma viruses in prostate cancer. Case control serological studies with normal sera as controls

From: Evidence for a causal role by human papillomaviruses in prostate cancer – a systematic review

Study Country Prostate cancer Controls Main HPV types P value
Dillner 1998 [52] Finland 21/165 13% 36/290 12% 16,18,33 0.865 ns
Hisada 2000 [53] US 20/48 42% 19/63 30% 16 0.253 ns
Hayes 2000 [54] US 19/276 7% 15/295 5% 16 0.393 ns
Rosenblatt 2003 [55] US 81/642 13% 64/570 11% 16,18 0.347 ns
Adami 2003 [56] Sweden 69/238 29% 48/210 23% 16,18,33 0.212 ns
Korodi 2005 [57] Sweden 107/799 13% 363/2596 14% 16,18,33 0.482 ns
Sutcliffe 2007 [58] US 107/584 18% 114/577 20% 16,18,33 0.696 ns
Sitas 2007 [59] South Africa 139/205 68% 390/673 58% 16 0.001 s
Huang 2008 [60] US 154/868 18% 310/1283 24% 16,18 −0.002 s
Dennis 2009 [61] US 50/267 19% 45/267 17%   0.637 ns
Sutcliffe 2010 [62] US 23/616 4% 22/616 4% 16,18,31 0.686 ns
Chen 2011 [12] Australia 29/53 55% 41/104 39% 16,18,31,33,52,58 0.131 ns
Hrbacek 2011 [63] Czech 167/316 53% 69/101 68% 16,18,31,33 −0.161 ns
Tachezy 2012 [28] Czech 14/50 28% 37/173 22% 16,18,31,33 0.445 ns
Zhao 2017 [64] China 48/75 64% 14/80 17.5% 16 0.001 s
  1. s = significant at p = 0.05. ns = not significant